Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MEDICAL-CLAIMS DATABASES IN THE DESIGN OF A HEALTH-OUTCOMES COMPARISON OF QUETIAPINE (SEROQUEL) AND USUAL-CARE ANTIPSYCHOTIC MEDICATION
Autore:
HONG WW; RAK IW; CIURYLA VT; WILSON AM; KYLSTRA JW; MELTZER HY; CARPENTER WT; LEHMAN A; ARVANITIS LA;
Indirizzi:
ZENECA PHARMACEUT,1800 CONCORD PIKE,POB L15437 WILMINGTON DE 19850 ZENECA PHARMACEUT WILMINGTON DE 19850 CASE WESTERN RESERVE UNIV,SCH MED,DEPT PSYCHIAT CLEVELAND OH 44106 MARYLAND PSYCHIAT RES CTR BALTIMORE MD 21228 UNIV MARYLAND,SCH MED,DEPT PSYCHIAT BALTIMORE MD 21201
Titolo Testata:
Schizophrenia research
fascicolo: 1, volume: 32, anno: 1998,
pagine: 51 - 58
SICI:
0920-9964(1998)32:1<51:MDITDO>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEUROLEPTIC-RESISTANT SCHIZOPHRENIA; REVOLVING-DOOR PATIENTS; COST; CLOZAPINE; COHORT;
Keywords:
SCHIZOPHRENIA; HEALTH-CARE COSTS; DRUG COSTS; EXTRAPYRAMIDAL TRACTS, DRUG EFFECTS; QUETIAPINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Citazioni:
31
Recensione:
Indirizzi per estratti:
Citazione:
W.W. Hong et al., "MEDICAL-CLAIMS DATABASES IN THE DESIGN OF A HEALTH-OUTCOMES COMPARISON OF QUETIAPINE (SEROQUEL) AND USUAL-CARE ANTIPSYCHOTIC MEDICATION", Schizophrenia research, 32(1), 1998, pp. 51-58

Abstract

Treating schizophrenia is expensive. Preventing rehospitalization of patients with schizophrenia provides an attractive opportunity for cost savings, especially for patients with 'revolving-door' or multiple-episode schizophrenia. Reducing the occurrence of extrapyramidal symptoms and other adverse events associated with standard antipsychotic agents may increase compliance and reduce the rate of rehospitalization of patients with schizophrenia. Quetiapine ('Seroquel', ICI 204,636, Zeneca Pharmaceuticals) is a new dibenzothiazepine antipsychotic agent with a low propensity for extrapyramidal symptoms. We describe here a unique methodology to compare quetiapine with usual-care medications inreal-world treatment settings. The trial objective is to determine iftherapy with this new atypical antipsychotic agent can reduce the rate of rehospitalization and, therefore, treatment costs. Using two secondary medical-claims databases, we defined the minimal threshold for revolving-door status as 1.0 admission per year; this definition allowsour trial to focus on the subpopulation of schizophrenic patients with the greatest potential for cost savings by either the new atypical antipsychotic quetiapine or usual-care therapy. We describe here the approach used in our trial. (C) 1998 Published by Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 00:32:44